Type 1 Diabetes Mellitus Maturity Onset Clinical Trial
Official title:
Smartguard Use in Real Life : a Longitudinal Study in Patients With Type 1 Diabetes
The reference treatment of the type 1 diabetes is intensified insulin therapy by insulin
pump. The CGM (continuous glucose monitoring) is a technology available for a decade, which
allows the continuous measure of interstitial glucose rate. The results are available in real
time to the user, who can so use them to optimize the adjustment of its treatment by insulin
pump. Since a few years, several research programs aim for finalizing an automated system
using the data of real time interstitial glucose to adjust automatically, via an algorithm,
the release of insulin by the pump. This type of closed-loop system is for the moment only
experimental, not still widely available in routine. On the other hand, rudimentary
regulation systems partially automated already exist and can be used in common clinical
practice. One of these systems, Smartguard ®, allows this type of regulation to decrease the
hypoglycemic risk of the patients treated by insulin pump. It is indeed a hypo minimizer
which interrupts the basal output when the algorithm embarked on the pump determines thanks
to the CGM data what a hypoglycemia risks to occur in the 30 minutes. The efficiency of this
system to reduce hypoglycemias was proved by several studies in pediatric and adult
populations of subjects with DT1 (Diabetes Care on 2015; 38:1197-1204. J Diabetes Sci
Technol. 2016 May 20. Pii: 1932296816645119). However, to date, there are no published data
concerning the method of use of this system (sensor et pump initial configuration; patient
education), nor the evolution of the sensor and pump parameters during the use.
The aim of this observationnelle study is to collect the data of efficiency, safety and use
of the system Smartguard ® in common clinical practice in an adult population of subjects
DT1.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT06006468 -
Evaluating ImmuNe Changes in the Evolution of Pre Type 1 Diabetes With Adult ONset
|
||
| Completed |
NCT05252728 -
Altered Faecal Microbiome and Metabolome in CT1D, AT1D and T2D
|